Millennium Management LLC Sells 101,671 Shares of Harrow, Inc. (NASDAQ:HROW)

Millennium Management LLC cut its stake in Harrow, Inc. (NASDAQ:HROW) by 60.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,262 shares of the company’s stock after selling 101,671 shares during the period. Millennium Management LLC owned 0.19% of Harrow worth $2,257,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of HROW. Barclays PLC raised its stake in shares of Harrow by 301.9% in the third quarter. Barclays PLC now owns 52,593 shares of the company’s stock worth $2,365,000 after acquiring an additional 39,506 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Harrow by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company’s stock worth $253,000 after acquiring an additional 727 shares during the last quarter. Calamos Advisors LLC raised its stake in shares of Harrow by 35.2% in the fourth quarter. Calamos Advisors LLC now owns 11,913 shares of the company’s stock worth $400,000 after acquiring an additional 3,103 shares during the last quarter. Bleakley Financial Group LLC grew its position in shares of Harrow by 63.1% during the 4th quarter. Bleakley Financial Group LLC now owns 8,770 shares of the company’s stock worth $294,000 after buying an additional 3,394 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Harrow by 8.4% during the 4th quarter. Bank of New York Mellon Corp now owns 86,447 shares of the company’s stock worth $2,900,000 after buying an additional 6,690 shares during the period. 72.76% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on HROW. B. Riley lowered their price target on shares of Harrow from $69.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. HC Wainwright lifted their price target on shares of Harrow from $57.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, May 12th.

Harrow Stock Up 3.8%

Shares of NASDAQ HROW opened at $28.24 on Monday. The stock has a market cap of $1.04 billion, a P/E ratio of -30.04 and a beta of 0.41. The firm has a 50 day moving average price of $25.18 and a 200 day moving average price of $30.30. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. Harrow, Inc. has a 52-week low of $16.71 and a 52-week high of $59.23.

Harrow (NASDAQ:HROW) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.40). The company had revenue of $47.83 million during the quarter, compared to analyst estimates of $57.00 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. Analysts expect that Harrow, Inc. will post -0.53 EPS for the current year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.